ACRV Institutional Ownership
Acrivon Therapeutics, Inc.
Latest close $1.73 as of Aug 7, 2026
ACRV institutional ownership at a glance
Follow Acrivon Therapeutics, Inc. institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.
Latest filing: Citadel Advisors filed Schedule 13G amendment on May 15, 2026, reporting 13 shares and 0.00% beneficial ownership.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Institutional Research
This gauge summarizes recent agreement across tracked institutional activity.
1 exited across 1 comparable institution.
The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.
Price context
52-week position is market context and does not change the institutional consensus score.
Tracked institutions
Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.
Beneficial ownership filing history
Showing 3 of 4 filing(s) · 1 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Citadel Advisors CIK0001423053 | Mar 31, 2026 observed May 15, 2026 filed · 45d Schedule 13G amendment | Exit below reporting threshold | 13 -1.7M | 0.00% -5.50 pts | $1.39 | $1.77 | $1.73 |
| Citadel Advisors CIK0001423053 | Nov 14, 2025 observed Nov 21, 2025 filed · 7d Initial Schedule 13G | Initial Schedule 13G | 1.7M +180.5K | 5.50% +0.60 pts | $2.24 | $2.30 | $1.73 |
| Citadel Advisors CIK0001423053 | Sep 30, 2025 observed Nov 14, 2025 filed · 45d Schedule 13G amendment | Exit below reporting threshold | 1.5M -354.3K | 4.90% -1.10 pts | $1.81 | $2.24 | $1.73 |
Related research
Compare ACRV with other securities showing similar institutional activity or recent accumulation across several tracked institutions.